(MedPage Today) — SAN FRANCISCO — The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed.
The trial tested two doses of…
Source link : https://www.medpagetoday.com/meetingcoverage/aanem/118269
Author :
Publish date : 2025-11-01 20:00:00
Copyright for syndicated content belongs to the linked Source.
